The Trump administration has moved to end federal taxpayer funding for medical gender-transition interventions for minors, arguing that children should be protected from treatments carrying potentially irreversible consequences. The decision comes amid a wider international reassessment of the evidence supporting medical transition of children and adolescents.
INR Report: Based on reporting by RT HERE
US President Donald Trump has ordered an end to federal funding for what is commonly described as "gender-affirming care" for minors through Medicaid and the Children's Health Insurance Program (CHIP).
The restrictions are scheduled to take effect on October 13, 2026, and cover puberty blockers, cross-sex hormones and surgical procedures.
Children already receiving hormone treatment will be given a transition period of up to six months, while federal funding for mental-health services will remain available. Individual US states will also remain free to use their own funds for treatments that will no longer qualify for federal reimbursement.
Trump said taxpayers should not be required to finance procedures that his administration considers capable of causing irreversible harm to children.
The Centers for Medicare and Medicaid Services said the policy followed a Department of Health and Human Services review which identified significant gaps in the evidence supporting medical gender transition for minors and concerns surrounding potentially irreversible effects.
CMS Administrator Mehmet Oz said the administration's position was that children should not be subjected to medical interventions where benefits have not been sufficiently demonstrated and significant risks may exist.
A Changing Medical Debate
The issue remains strongly contested in the United States. Major medical organisations continue to support access to gender-related treatment based on individual clinical circumstances, while critics argue that the evidence supporting medical intervention in children remains insufficient.
The debate is increasingly focused not simply on transgender rights, but on a fundamental medical question: what level of evidence should be required before children are given treatments that may affect their physical development, fertility and future sexual function?
This question has become increasingly important as medical authorities in several countries reassess the evidence underpinning the treatment of children and adolescents experiencing gender dysphoria.
New Zealand Has Already Changed Course
The development has particular relevance to New Zealand.
New Zealand's Ministry of Health conducted an evidence review of puberty blockers for adolescents with gender dysphoria and concluded there were significant limitations in the quality of evidence concerning both their benefits and risks.
That reassessment subsequently produced a major policy change.
Since December 19, 2025, New Zealand regulations have restricted new prescriptions of GnRH analogue puberty blockers for puberty suppression in children and adolescents with gender incongruence or gender dysphoria, subject to limited exceptions. Young people already receiving treatment may continue under existing arrangements.
Government briefing documents have acknowledged that high-quality evidence remains limited regarding both the long-term benefits and risks of these treatments in this population.
Does This Affect New Zealand?
Yes — because New Zealand is already confronting many of the same questions now driving US policy.
The central issue is not whether young people experiencing gender dysphoria deserve compassion and appropriate healthcare. They clearly do. The question is whether medical interventions affecting a developing child's body should proceed when the long-term evidence remains uncertain.
New Zealand's Ministry of Health has itself acknowledged limitations in the available evidence and adopted a more precautionary regulatory approach.
The US decision therefore forms part of a broader international reconsideration of how medicine should respond to gender dysphoria in children — particularly where treatments may have lasting consequences.
Whatever one's political position, the principle deserves serious consideration: when medicine involves children and potentially irreversible interventions, the evidential threshold should be exceptionally high if at all.
Independent reporting. Original context. Credited sources.